Andrew M. Scharenberg, MD, is attending physician at Seattle Children’s Hospital, professor in the Department of Pediatrics and adjunct professor in the Department of Immunology at the University of Washington School of Medicine, and a member of the Transplantation Biology Consortium Program at Fred Hutchinson Cancer Research Center. He earned his MD with distinction from the University of North Carolina School of Medicine, performed his residency training in pediatrics at the University of North Carolina Children’s Hospital, and completed a fellowship in immunology at NIH and at the Division of Experimental Pathology, Beth Israel Hospital. He participates in the Seattle Children’s Immunodeficiency Clinic and the Inpatient Immunology Consult Service. At Seattle Children’s Research Institute, he operates a 12-member laboratory that develops technology for targeted genome editing, and co-directs the Program in Cell and Gene Therapy, a program to translate cell and gene therapies for the treatment of inherited immunologic and blood diseases. Dr. Scharenberg is past co-founder of the gene editing pioneer Pregenen Inc, acquired by bluebird bio in 2014. He received the American Pediatric Society/Society for Pediatric Research National Young Investigator Award in 2002; and is an active member of the American Society for Clinical Investigation and the American Pediatric Society.

Contact Info

Research Areas

LAB

Pubmed